Elutia outlines plan for NXT-41x launch in $1.5B breast reconstruction market following $88M asset sale
Source: SeekingAlpha
2025-11-07 00:16:54 ET
More on Elutia
- Elutia Inc. (ELUT) Q3 2025 Earnings Call Transcript
- Elutia Inc. (ELUT) Presents at LD Micro Main Event XIX Investor Conference - Slideshow
- Elutia Inc. (ELUT) Presents at H.C. Wainwright 27th Annual Global Investment Conference - Slideshow
- Boston Scientific buys Elutia's bioenvelope business for $88 million
- Elutia targets $20M EluPro revenue run rate and NXT-41 launch in H2 2026 while advancing hospital penetration
Read the full article on Seeking Alpha
For further details see:
Elutia outlines plan for NXT-41x launch in $1.5B breast reconstruction market following $88M asset sale
Elutia Inc.
NASDAQ: ELUT
ELUT Trading
1.8% G/L:
$1.13 Last:
113,904 Volume:
$1.09 Open:
ELUT Latest News
March 02, 2026 08:00:00 am
Elutia Selects Pete Ligotti as CCO to Lead the Commercial Launch of NXT-41x and Transform Post-Mastectomy Care in the $1.5B U.S. Breast Surgery Market
February 25, 2026 04:05:00 pm
Elutia to Report Fourth Quarter 2025 Financial Results on Wednesday, March 11, 2026
February 18, 2026 08:00:00 am
Where Purpose Meets Performance: Elutia Earns 2026 Great Place to Work Certification(TM)
ELUT Stock Data
$40,570,396
24,688,117
4.16%
15
N/A
Medical Equipment & Supplies
Healthcare
US
Gaithersburg
